CDE News - Your News Feed

AstraZeneca’s trial illnesses may not be due to COVID-19 shot – Oxford University

The adverse events that led to a pause in trials evaluating AstraZeneca Plc's COVID-19 vaccine candidate may not have been associated with the vaccine itself, according to a document outlining…

Read More from CDE News

Coronavirus, ItalyAstraZeneca, Coronavirus, Italy, vaccine

Italy could have AstraZeneca COVID-19 vaccine by end November

Italy could have its first shots of British drugmaker AstraZeneca's potential COVID-19 vaccine by the end of November, the managing director of IRBM told Reuters. Biotech firm IRBM, whose lab…

Read More from CDE News

CD eNews, Comuniq.EU, CoronavirusAstraZeneca, Coronavirus, UK, vaccine

EU medical register shows AstraZeneca’s UK COVID-19 vaccine trials restarted

AstraZeneca's British clinical trials of its COVID-19 vaccine, one of the most advanced in development, resumed on Monday, according to the European clinical trials database EudraCT. The trial's status changed…

Read More from CDE News

CD eNews, Coronavirus, World Health Organization (WHO)AstraZeneca, Coronavirus, vaccine, WHO

AstraZeneca vaccine trial pause a “wake-up call”, says WHO

AstraZeneca's pause of an experimental vaccine for the coronavirus after the illness of a participant is a "wake-up call" but should not discourage researchers, the World Health Organization's (WHO) chief…

Read More from CDE News

CD eNews, Coronavirus, UKAstraZeneca, Coronavirus, UK, vaccine

AstraZeneca says should know if vaccine works by year-end if trials resume

AstraZeneca should still know before the end of the year whether its experimental vaccine protects people against COVID-19, the drugmaker's chief executive Pascal Soriot said on Thursday, as long as…

Read More from CDE News

CD eNews, Coronavirus, UKAstraZeneca, Coronavirus, UK, vaccine

UK says other vaccine trials also likely to be paused

Other COVID-19 vaccine trials are likely to be paused at some point the British government’s Chief Scientific Adviser Patrick Vallance, said, describing a pause in the trial of an AstraZeneca…

Read More from CDE News

Australia, CoronavirusAstraZeneca, Australia, vaccine

Australia says not worried about AstraZeneca’s suspension of COVID vaccine trials

AstraZeneca Plc's suspension of its COVID-19 vaccine trials after a participant's unexplained illness did not mean the vaccine had been scrapped and showed safety standards were being adhered to, Australia's…

Read More from CDE News

CD eNews, Coronavirus, WHOAstraZeneca, Coronavirus, vaccine, WHO

UPDATED: WHO says vaccine safety top priority, as AstraZeneca pauses study

Safety of a prospective vaccine for COVID-19 comes "first and foremost", the World Health Organization's chief scientist said on Wednesday, as a trial of a candidate from AstraZeneca was paused,…

Read More from CDE News

Coronavirus, UKAstraZeneca, UK, vaccine

UK health minister says pause in AstraZeneca vaccine trial not necessarily a setback

Britain's Health Secretary Matt Hancock said on Wednesday that AstraZeneca's decision to pause its coronavirus vaccine trials was a challenge but would not necessarily set back efforts to develop a…

Read More from CDE News

CD eNews, Coronavirus, UKAstraZeneca, Coronavirus, vaccine

AstraZeneca puts leading COVID-19 vaccine trial on hold over safety concern

AstraZeneca Plc announced it has paused a late-stage trial of one of the leading COVID-19 vaccine candidates after an unexplained illness in a study participant. "Our standard review process was…

Read More from CDE News

Australia, CoronavirusAstraZeneca, Australia, Coronavirus, vaccine

Australia expects to receive AstraZeneca’s COVID-19 vaccine within months

Australia expects to receive its first batches of a potential COVID-19 vaccine in January, Prime Minister Scott Morrison said on Monday, as the number of new daily infections in the…

Read More from CDE News

Coronavirus, JapanAstraZeneca, Coronavirus, Japan, vaccine

Astrazeneca to begin Phase 1/2 clinical trials of coronavirus vaccine in Japan

Astrazeneca said on Friday it is beginning Phase 1/2 clinical trials in Japan of its coronavirus vaccine candidate. Trials of the vaccine, known as AZD1222, will be conducted at multiple…

Read More from CDE News

CD EUAstraZeneca, EU

EU secures AstraZeneca’s potential COVID-19 vaccine

The European Commission has made a 336 million euro ($396 million) downpayment to British drug maker AstraZeneca to secure at least 300 million doses of its potential COVID-19 vaccine, a…

Read More from CDE News

Argentina, Coronavirus, Mexico, NewsArgentina, AstraZeneca, Mexico, vaccine

Argentina and Mexico to produce AstraZeneca COVID-19 vaccine

Argentina and Mexico will produce the AstraZeneca COVID-19 vaccine for most of Latin America, Argentine President Alberto Fernandez announced after a meeting with company executives involved in the project. An…

Read More from CDE News

Coronavirus, NewsAstraZeneca, Coronavirus, vaccine

A look at AstraZeneca’s potential coronavirus vaccine

AstraZeneca signed its first COVID-19 vaccine supply deal with a Chinese company, Kangtai Bio, opening up distribution to one of the world's most populous countries. Drugmakers are racing to combat…

Read More from CDE News

CD eNews, CoronavirusAstraZeneca, Coronavirus

AstraZeneca to be exempted from coronavirus vaccine liability claims in most countries

AstraZeneca has been granted protection from future product liability claims related to its COVID-19 vaccine hopeful by most of the countries it has so far struck supply agreements with, a…

Read More from CDE News

Coronavirus, France, NewsAstraZeneca, Coronavirus, France, vaccine

France expects AstraZeneca COVID-19 vaccine to be shared pro rata

A deal between AstraZeneca and France over potential COVID-19 vaccines foresees doses being split between countries on a pro-rata basis based on population, a source at the French President's office…

Read More from CDE News

Coronavirus, News, UKAstraZeneca, vaccine

AstraZeneca in talks with Japan, Russia, Brazil and China on COVID-19 vaccine supplies

AstraZeneca is in talks with Japan, Russia, Brazil and China about supply deals for its potential coronavirus vaccine, its chief said on Saturday, as the British drugmaker prepares to publish…

Read More from CDE News

CD eNews, Coronavirus, Corporate Dispatch, NewsAstraZeneca, Bill Gates, Coronavirus

AstraZeneca boosts potential supply to 2 billion in two deals involving Microsoft billionaire Bill Gates

British drugmaker AstraZeneca has doubled manufacturing capacity for its potential coronavirus vaccine to 2 billion doses in two deals involving Microsoft billionaire Bill Gates that guarantee early supply to lower income countries.…

Read More from CDE News

Coronavirus, NewsAstraZeneca, Coronavirus

AstraZeneca pilots diabetes drug as potential COVID-19 treatment

Britain’s AstraZeneca is testing a diabetes drug as a potential treatment for COVID-19 patients who also had existing heart and kidney problems, its second trial of an approved therapy to…

Read More from CDE News

Coronavirus, NewsAstraZeneca, Coronavirus

AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19

AstraZeneca will initiate a randomised, global clinical trial to assess the potential of Calquence (acalabrutinib) in the treatment of the exaggerated immune response (cytokine storm) associated with COVID-19 infection in…

Read More from CDE News

Healthcare, News, UKAmgen, AstraZeneca, Genetics, GlaxoSmithKline, Johnson&Johnson, UK, UK Biobank

World’s largest genetics project to tackle deadly diseases launched in the UK

A new ground-breaking project in the fight against life-threatening illnesses has launched today in the UK. The £200 million whole genome sequencing project is being created, forming a partnership of…

Read More from CDE News

Healthcare, NewsAstraZeneca, blood cancer, Calquence, lymphocytic leukaemia

Successful trials for AstraZeneca’s blood cancer drug continue

AstraZeneca Plc announced its blood cancer drug met the primary endpoint of a final stage trial, the second success for the treatment in a month. The drug, Calquence, showed meaningful…

Read More from CDE News